A new type of cholesterol drug worked in study, Merck announces


In this Thursday, Dec.18, 2014, file photograph, scientist Christopher Kistler checks on experiments in AMBR250 bio-reactors in a laboratory at the Merck company facilities in Kenilworth, N.J. The bio-reactors allow a large number of experiments to be done in the lab at the same time. On Tuesday, June 27, 2017, Merck & Co.



from Biotech News